ReviewTexas Heart Institute journal2022
Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use.
Review in Texas Heart Institute journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of positive gastrointestinal contrast media. Updated guidelines by the ESUR Contrast Media Safety Committee.European radiology · 2026Guideline
- Magnetic nanoparticle contrast agents for MRI: structure-property relationships,Nanotechnology · 2026Review
- Review
- Metabolic Gadolinium Labeling ofBiomaterials research · 2026Article
- The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management.Cureus · 2026Review
- Clinical utility of segmental native T1 mapping for diagnosis and risk-stratification in cardiac sarcoidosis.International journal of cardiology. Heart & vasculature · 2025Article
- Simultaneous TMagnetic resonance in medicine · 2025Article
- Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.Nanomaterials (Basel, Switzerland) · 2025Review
- Shedding Light on Hidradenitis Suppurativa Activity: A Pilot Study to Evaluate the Potential of [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Detection of cerebral cavernous malformation associated developmental venous anomalies in gradient-echo and susceptibility-weighted magnetic resonance imaging: can we skip the contrast?Neuroradiology · 2025Article
- Deep learning approaches for the detection of scar presence from cine cardiac magnetic resonance adding derived parametric images.Medical & biological engineering & computing · 2025Article
- Development of Ln(III) Derivatives asInorganic chemistry · 2024Article
- In Vivo Evaluation of Innovative Gadolinium-Based Contrast Agents Designed for Bioimaging Applications.Polymers · 2024Article
- Safe and Informed Use of Gadolinium-Based Contrast Agent in Body Magnetic Resonance Imaging: Where We Were and Where We Are.Journal of clinical medicine · 2024Review
- Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review.European journal of radiology open · 2023Review
- Tannic acid-mediated synthesis of flower-like mesoporous MnOScientific reports · 2023Article
- Article
- [Magnetic resonance arthrography with physiological saline solution in the diagnosis of temporomandibular joint disc perforation. Case report].Revista cientifica odontologica (Universidad Cientifica del Sur)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium-based contrast agents have expanded the diagnostic usefulness and capability of magnetic resonance imaging. Despite their highly favorable safety profile, these agents have been associated with nephrogenic systemic fibrosis in a small number of patients who have advanced kidney disease. Recently, trace amounts of gadolinium deposition in the brain and other organs have been reported after contrast exposure, even in patients with normal renal function. In this review, we provide a brief overview of recent updates and discuss typical clinical situations related to the use of gadolinium-based contrast agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.